TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the recipient of a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 24,700 shares, a decline of 85.2% from the June 30th total of 167,200 shares. Approximately 0.4% of the company’s shares are sold short. Based on an average daily trading volume, of 1,400,000 shares, the short-interest ratio is presently 0.0 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of TransCode Therapeutics in a research note on Wednesday, May 29th.
View Our Latest Analysis on RNAZ
Institutional Investors Weigh In On TransCode Therapeutics
TransCode Therapeutics Stock Performance
Shares of NASDAQ RNAZ remained flat at $0.30 during trading hours on Thursday. The company had a trading volume of 1,270,871 shares, compared to its average volume of 981,876. The company’s 50 day moving average price is $1.09 and its 200-day moving average price is $1.06. TransCode Therapeutics has a 1-year low of $0.29 and a 1-year high of $128.00.
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.05. On average, analysts predict that TransCode Therapeutics will post -1.98 EPS for the current year.
About TransCode Therapeutics
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Read More
- Five stocks we like better than TransCode Therapeutics
- 3 Best Fintech Stocks for a Portfolio Boost
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- What is the Dogs of the Dow Strategy? Overview and Examples
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- NYSE Stocks Give Investors a Variety of Quality Options
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.